MaxCyte, Inc. License with Nkarta, Inc. (6206Q)
October 28 2021 - 10:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 6206Q
MaxCyte, Inc.
28 October 2021
MaxCyte Signs Strategic Platform License with Nkarta, Inc.
to Advance Natural Killer Cell Therapy Programs
Nkarta to use MaxCyte's Flow Electroporation (R) technology and
ExPERT(TM) platform to accelerate the development of its oncology
cell-therapy candidates
South san francisco and GAITHERSBURG, MD, October 28, 2021 -
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider
of enabling platform technologies for ex-vivo cell engineering,
today announces the signing of a strategic platform license (SPL)
with Nkarta, Inc., a biopharmaceutical company developing
engineered natural killer (NK) cell therapies to treat cancer.
Under the terms of the agreement, Nkarta obtains non-exclusive
clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related milestone payments.
The Nkarta approach maximizes the therapeutic effect of
allogeneic NK cells through robust expansion, enhanced targeting
and extended persistence resulting in potent immune cells that
enable a sustained anti-cancer immune-mediated attack.
"Broad access to the most powerful and promising enabling
technologies is critical to our success and the innovation of
next-generation NK cell therapies for cancer patients," said Paul
J. Hastings, Nkarta's President and CEO. "MaxCyte's electroporation
technology leads the field and we're excited to leverage the
advantages of their transfection technology with our integrated
cell engineering platform ."
Doug Doerfler, President and CEO of MaxCyte, said: "We are proud
to support Nkarta's pioneering platform that has the potential to
boost the body's immune response to fight cancer. Our team is
thrilled to be working with a leader in developing novel products
leveraging the unique power of NK cells for the treatment of
patients with cancer."
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically-validated, electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Nkarta, Inc. is MaxCyte's 15th SPL adding to
three MaxCyte partnerships year-to-date, which generate
pre-commercial milestone revenue and the vast majority of which
include post-commercial revenue.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: three instruments, the ATx(TM), STx(TM) and
GTx(TM); a portfolio of proprietary related processing assemblies
or disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com
US Media Relations
Laura Morgan +1 951-333-9110
Sam Brown Healthcare Communications lauramorgan@sambrown.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEADEPADAFFFA
(END) Dow Jones Newswires
October 28, 2021 10:00 ET (14:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024